> Skip to content
FEATURED:
  • Philanthropy 50
  • Nonprofits and the Trump Agenda
  • Impact Stories Hub
Sign In
  • Latest
  • Commons
  • Advice
  • Opinion
  • Webinars
  • Online Events
  • Data
  • Grants
  • Magazine
  • Store
    • Featured Products
    • Data
    • Reports
    • Collections
    • Back Issues
    • Webinars
    • Featured Products
    • Data
    • Reports
    • Collections
    • Back Issues
    • Webinars
  • Jobs
    • Find a Job
    • Post a Job
    • Career Advice
    • Find a Job
    • Post a Job
    • Career Advice
Sign In
  • Latest
  • Commons
  • Advice
  • Opinion
  • Webinars
  • Online Events
  • Data
  • Grants
  • Magazine
  • Store
    • Featured Products
    • Data
    • Reports
    • Collections
    • Back Issues
    • Webinars
    • Featured Products
    • Data
    • Reports
    • Collections
    • Back Issues
    • Webinars
  • Jobs
    • Find a Job
    • Post a Job
    • Career Advice
    • Find a Job
    • Post a Job
    • Career Advice
  • Latest
  • Commons
  • Advice
  • Opinion
  • Webinars
  • Online Events
  • Data
  • Grants
  • Magazine
  • Store
    • Featured Products
    • Data
    • Reports
    • Collections
    • Back Issues
    • Webinars
    • Featured Products
    • Data
    • Reports
    • Collections
    • Back Issues
    • Webinars
  • Jobs
    • Find a Job
    • Post a Job
    • Career Advice
    • Find a Job
    • Post a Job
    • Career Advice
Sign In
ADVERTISEMENT
The Face of Philanthropy
  • Twitter
  • LinkedIn
  • Show more sharing options
Share
  • Twitter
  • LinkedIn
  • Email
  • Facebook
  • Copy Link URLCopied!
  • Print

Nonprofit Powers Creation of Low-Cost Covid Vaccine

By  Emily Haynes
June 1, 2021
Lab workers test vaccine.
GPO

Philanthropy is powering development of a new low-cost Covid-19 vaccine, now in clinical trials in Thailand and Vietnam, with another soon to start in Brazil. PATH, a nonprofit that works to advance equity in global public health, is using its connections with international government agencies, vaccine manufacturers, and scientists to create a coronavirus vaccine that can be manufactured in lower-income countries.

“We have some highly effective, incredible vaccines that exist,” says Carla Costa Sandine, chief of external affairs at PATH. “But right now, the majority of the world’s population doesn’t have access to them.”

We're sorry. Something went wrong.

We are unable to fully display the content of this page.

The most likely cause of this is a content blocker on your computer or network.

Please allow access to our site, and then refresh this page. You may then be asked to log in, create an account if you don't already have one, or subscribe.

If you continue to experience issues, please contact us at 571-540-8070 or cophelp@philanthropy.com

Philanthropy is powering development of a new low-cost Covid-19 vaccine, now in clinical trials in Thailand and Vietnam, with another soon to start in Brazil. PATH, a nonprofit that works to advance equity in global public health, is using its connections with international government agencies, vaccine manufacturers, and scientists to create a coronavirus vaccine that can be manufactured in lower-income countries.

“We have some highly effective, incredible vaccines that exist,” says Carla Costa Sandine, chief of external affairs at PATH. “But right now, the majority of the world’s population doesn’t have access to them.”

To date, nearly 42 percent of the global vaccine doses administered have inoculated people living in high-income countries, like the United States, according to the Global Change Data Lab. Upper-middle income countries, like China, claim another 42 percent, while less than 1 percent have been administered in low-income countries, such as Afghanistan.

Unlike the three vaccines currently going into arms in the United States, the new NDV-HXP-S vaccine that PATH is supporting — NDV for short — can be created in a chicken egg, like a flu vaccine. What’s more, it doesn’t need to be stored at ultra-low temperatures.

ADVERTISEMENT

This is all good news for low-income countries like Thailand and Vietnam, which already manufacture flu vaccines and have the systems in place to store and distribute it. Thanks to that infrastructure, Thailand alone could manufacture as many as 30 million annual doses of the vaccine by 2022, Costa Sandine says.

But there is a catch: PATH estimates that these vaccines won’t clear clinical trials and be ready for mass inoculations until next year. Donors and global governments need to support development of low-cost vaccines like NDV while also contributing to the WHO’s Covax campaign to funnel existing doses to people in the developing world, she says.

Time is of the essence, Costa Sandine says. “We have to do both things at once.”

A version of this article appeared in the June 1, 2021, issue.
We welcome your thoughts and questions about this article. Please email the editors or submit a letter for publication.
Foundation GivingFundraising from Individuals
Emily Haynes
Emily Haynes is senior editor of nonprofit intelligence at the Chronicle of Philanthropy, where she covers nonprofit fundraising.
ADVERTISEMENT
ADVERTISEMENT
SPONSORED, GEORGE MASON UNIVERSITY
  • Explore
    • Latest Articles
    • Get Newsletters
    • Advice
    • Webinars
    • Data & Research
    • Podcasts
    • Magazine
    • Chronicle Store
    • Find a Job
    • Impact Stories
    Explore
    • Latest Articles
    • Get Newsletters
    • Advice
    • Webinars
    • Data & Research
    • Podcasts
    • Magazine
    • Chronicle Store
    • Find a Job
    • Impact Stories
  • The Chronicle
    • About Us
    • Our Mission and Values
    • Work at the Chronicle
    • User Agreement
    • Privacy Policy
    • California Privacy Policy
    • Gift-Acceptance Policy
    • Gifts and Grants Received
    • Site Map
    • DEI Commitment Statement
    • Chronicle Fellowships
    • Pressroom
    The Chronicle
    • About Us
    • Our Mission and Values
    • Work at the Chronicle
    • User Agreement
    • Privacy Policy
    • California Privacy Policy
    • Gift-Acceptance Policy
    • Gifts and Grants Received
    • Site Map
    • DEI Commitment Statement
    • Chronicle Fellowships
    • Pressroom
  • Customer Assistance
    • Contact Us
    • Advertise With Us
    • Post a Job
    • Reprints & Permissions
    • Do Not Sell My Personal Information
    • Advertising Terms and Conditions
    Customer Assistance
    • Contact Us
    • Advertise With Us
    • Post a Job
    • Reprints & Permissions
    • Do Not Sell My Personal Information
    • Advertising Terms and Conditions
  • Subscribe
    • Individual Subscriptions
    • Site License Subscriptions
    • Subscription & Account FAQ
    • Manage Newsletters
    • Manage Your Account
    Subscribe
    • Individual Subscriptions
    • Site License Subscriptions
    • Subscription & Account FAQ
    • Manage Newsletters
    • Manage Your Account
1255 23rd Street, N.W. Washington, D.C. 20037
© 2025 The Chronicle of Philanthropy
  • twitter
  • instagram
  • youtube
  • facebook
  • linkedin